PALI

SEC Filing Summary: Neuralstem, Inc. (10-Q)

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for Neuralstem, Inc. for the period ended September 30, 2010. The company is a clinical-stage biotechnology firm focused on developing treatments based on human neural stem cells and small molecule compounds. As of the reporting date, the company had no commercial revenue and was primarily engaged in pre-clinical and clinical research, specifically a Phase I trial for Amyotrophic Lateral Sclerosis (ALS).

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Net Loss: The net loss for the nine months ended September 30, 2010, more than doubled compared to the prior year period. This was driven by a $2.76 million increase in non-cash warrant accounting charges, a $525,000 increase in stock-based compensation, and higher R&D and legal expenses.
• Operating Expenses: Total operating expenses increased by approximately 43% ($3.58 million). Research and Development (R&D) expenses rose 58% to $6.63 million, primarily due to the initiation of the ALS clinical trial and preparation for a spinal cord injury trial. General and Administrative (G&A) expenses increased 28% to $5.01 million, largely due to increased legal fees and stock-based compensation.
• Liquidity Improvement: Cash and cash equivalents increased by approximately $9.2 million (379%) from the prior year period. This surge was fueled by net financing proceeds of $16.7 million, derived from a registered direct offering and the exercise of outstanding warrants.
• Warrant Liability Reduction: The fair value of warrant obligations decreased from $6.46 million at year-end 2009 to $2.20 million at September 30, 2010, due to the exercise, expiration, and modification of warrants, despite a $2.04 million loss recorded from changes in fair value during the period.

Guidance, Outlook, and Risks

• Cash Runway: Management estimates sufficient cash to fund operations into the third quarter of 2011, assuming the second IND (spinal cord injury) is not commenced. The current monthly cash burn rate is approximately $800,000, expected to rise to $900,000 if the second trial begins.
• Clinical Progress:
  • ALS Trial: Phase I trial commenced in January 2010; 7 patients treated as of September 30, 2010. Safety data from the first cohort allowed progression to the second cohort.
  • Spinal Cord Injury: Second IND filed in August 2010 but placed on clinical hold by the FDA in October 2010 pending protocol modifications.
  • Depression: Planning for an IND filing for a small molecule compound in early 2011.
• Subsequent Events: In November 2010, the company was awarded three federal grants totaling $733,438 to support therapeutic discovery projects, including the depression treatment and ALS trials.
• Risks: The company faces significant risks regarding its ability to secure additional financing, the success of clinical trials, regulatory approval (FDA), and ongoing patent litigation with StemCells, Inc. The company is also transitioning from a "smaller reporting company" status, which will increase compliance costs (e.g., Sarbanes-Oxley Section 404) starting in 2011.

Investor Verification Checklist

• Capital Adequacy: Verify the timeline for the next capital raise given the $800k-$900k monthly burn rate and the Q3 2011 cash runway estimate.
• Regulatory Status: Confirm the status of the FDA clinical hold on the spinal cord injury IND and the timeline for resolution.
• Warrant Liability: Monitor the fair value of remaining warrant obligations, as fluctuations in stock price directly impact net income/loss.
• Legal Proceedings: Review updates on the patent infringement litigation with StemCells, Inc., which could impact intellectual property rights and incur significant legal costs.
• Grant Funding: Confirm receipt of the $733,438 in federal grants awarded in November 2010 and their specific allocation to R&D projects.